Published: April 2023 | Report Code: 12609 | Available Format: PDF | Pages: 212
The U.S. and European Union osteoporosis drugs market is growing due to the increasing prevalence rate of osteoporosis diseases, the growing geriatric population, the surging cases of obesity, the rising prevalence of lifestyle-associated diseases, and the mounting healthcare spending in the U.S. and the EU.
The U.S. osteoporosis drugs market size was valued at USD 6,210.4 million in 2022, and it is expected to increase to USD 9,105.2 million by 2030, advancing at a CAGR of 4.90% during the forecast period. This is due to the presence of a large number of industry giants, enhanced healthcare infrastructure, high investment by the government in the healthcare sector, and increased consciousness regarding the disease in the country.
Additionally, companies in the U.S. are continuously involved in boosting awareness of the disease and the development of drugs, and numerous initiatives aimed at educating women about the importance of bone health will further contribute to the market growth in the nation in the coming years.
On the other hand, the European Union osteoporosis drugs market size was valued at USD 2,965.4 million in 2022, and this number is further expected to increase to USD 4,265.4 million by 2030, advancing at a CAGR of 4.65% during the predicted period. This is ascribed to the growing aging population, changing lifestyles, rapid urbanization, and increasing awareness about osteoporosis care in the region.
Based on type, the bisphosphonates category accounts for the largest revenue share, and it is further expected to maintain its dominance in the coming years. This is because bisphosphonates have verified efficacy to minimize fracture risk at the hip, spine, and other non-vertebral skeletal sites, increase the survival rate, and decrease the significant risk of morbidity. Moreover, the growing count of women in the post-menopausal stage and a surge in the prevalence of bone diseases will further contribute to the demand for such drugs.
On the other hand, the RANK ligand inhibitors category will witness the fastest growth during the forecast period. This can be ascribed to the growing inorganic activities such as licensing agreements among players, the rising number of clinical trial approvals for biosimilars, and RANK ligand inhibitors can be utilized in combination with other drugs to convey the synergetic effect on the comprehensive treatment system. Furthermore, other benefits associated with RANKL include a decrease in osteoclastogenesis and osteoclast activity, thereby reducing bone resorption; and an upsurge in bone mineral density.
As per the WHO, healthcare expenditure is increasing across the globe, owing to the surging prevalence of diseases and the rising government and non-government initiatives. This leads to the improvement in healthcare infrastructure and the rise in affordability and accessibility of treatment and diagnosis for different medical conditions.
The U.S. and EU countries are investing a significant portion of their GDP in healthcare. Although there are huge variations among the healthcare spending of different countries, healthcare has been one of the primary focuses for all. Healthcare spending in these economies is considerably higher, which leads to the increased demand for osteoporosis drugs.
Based on application, the primary osteoporosis category accounts for a larger revenue share and it will also register faster growth during the forecast period. This is because the majority of cases that occurred are of the primary type, which affects women after menopause as a result of a sudden reduction in estrogen production; the loss of bone structure due to the lack of testosterone in men; and the growing aging population in the U.S. and the EU.
Osteoporosis leads to reduced bone strength and significant bone loss, which increase the risk of fractures. It affects people of both sexes and of all races/ethnicities. For instance, in the U.S. alone, there are around 2 million osteoporosis-related fractures, and the cost related to osteoporosis every year is around $19 billion.
According to the U.S. Department of Health and Human Services, an estimated 10 million individuals aged 50 years and older have osteoporosis in the country. Among these people, the majority of them are females, around 8 million, particularly menopausal women. In addition, over 43 million individuals, including 16 million males, have poor bone mass, which increases the risk of developing osteoporosis.
Furthermore, an estimated 1.5 million people experience a fracture as a result of a bone condition every year. Aging women are at the highest risk of developing fractures. A hip, spine, or wrist fracture occurs in about 4 in 10 White women in the U.S. who are 50 years or older at some point in their lives. The most common reason for fractures is osteoporosis.
Osteopenia of the hip, which affects 33.6 million people over the age of 50, puts them at risk for osteoporosis and its associated problems in later life. In the U.S., Black women had a lower age-adjusted osteoporosis prevalence and hip fracture rate than White women. Thus, the rising cases of osteoporosis drive the demand for related drugs.
Based on route of administration, the injectable category accounts for a larger revenue share, and it is further expected to maintain its position in the predicted period. This is because most of the drugs for osteoporosis come in the form of injectables. Additionally, this route of administration has several advantages such as injectable drugs do not cause stomach upset and it may be easier for some individuals to schedule a quarterly or yearly infusion than to reminisce to take a weekly or monthly pill.
On the other hand, the oral & spray category will witness significant growth during the coming years. This can be ascribed to the surging preference of individuals for oral & spray medication due to their ease of usage.
The U.S. market contributes a higher revenue share and it is also expected to maintain its dominance in the coming years. This is due to the high prevalence rate of bone-related diseases and osteoporosis-related fractures, the increasing number of hospitals and clinics, the rising government investment for developing advanced healthcare infrastructure, and the surging number of awareness programs in the country.
Moreover, the EU market will grow at a significant CAGR during the predicted period. This can be ascribed to the rising approvals for a number of medications by the European Medicines Agency, the increasing number of drug manufacturers, the mounting share of healthcare in the region’s GDP, and the growing elderly population coupled with osteoporosis-related fractures. In addition, Germany contributes the largest revenue share to the regional market, and it is further expected to maintain its dominance in the coming years. This is due to the presence of a large number of advanced medical device and drug providers, and the mounting patient consciousness regarding the disease.
This fully customizable report gives a detailed analysis of the U.S. and European Union osteoporosis drugs market from 2017 to 2030, based on all the relevant segments and geographies.
Based on Type
Based on Route of Administration
Based on Application
The U.S. osteoporosis drugs market size stood at USD 6,210.4 million in 2022.
During 2022–2030, the growth rate of the European Union osteoporosis drugs market will be 4.65%.
Bisphosphonates is the largest type in the U.S. and European Union osteoporosis drugs market.
The major drivers of the U.S. and European Union osteoporosis drugs market include the increasing healthcare expenditure, the high prevalence of osteoporosis, the growing geriatric population, and the rising number of clinical trials for such drugs in the U.S. and the EU.
Get a bespoke market intelligence solution
Want a report tailored exactly to your business strategy?Request Customization
Want an insight-rich discussion with the report author?Speak to Analyst
Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws